Back to Press
Previous
|
Next

Ascend Clinical Chooses Category Leaders, DeLorean AI and SambaNova, to Advance Renal Care With AI

Ascend leverages AI solution with deep learning models to classify, track and monitor renal care patients through disease states

March 16, 2022, HIMSS, Orlando, FL – SambaNova Systems and DeLorean Artificial Intelligence announce an AI solution to significantly advance renal care. Ascend Clinical, a leading dialysis testing laboratory, is the first customer to leverage the AI solution with deep learning models to classify, track and transition renal patients through disease states and provide recommended actions for treatment and care.

“We are committed to providing world-class care to our patients, so our laboratories need the most innovative technology,” said Paul F. Beyer, CEO of Ascend. “We’re looking forward to advancing our AI initiatives to provide a higher level of precision and improve our customers’ insights into their own data.”

The DeLorean AI Medical Renal Model running on SambaNova System’s platform ingests both structured and unstructured data from internal (Ascend or dialysis centers) and external sources like medical records, lab results, previous claims, procedural data, and others. The AI model predicts if a patient will be high or low-risk and then recommends the next best action for a care manager, nurse or healthcare professional. This is the first solution on the market to accurately predict risk, provide next best actions, and empower nursing management to hold caregivers accountable for their quality of care.

The financial implications of the AI model are significant, including decreased operating costs and a better customer experience for patients, resulting in a STAR Rating increase, Quality Bonus Payments (QBP), increased CMS Pay 4 Quality (P4Q) and increased revenue. Most importantly, patients benefit from a better quality of life and an extended lifespan.

“SambaNova and DeLorean’s medical AI solution is revolutionary— we’re bringing AI to an industry that truly needs it,” said Severence MacLaughlin, Ph.D, CEO & Founder at DeLorean Artificial Intelligence. “The solution will provide Ascend customers with value-based care by providing them with precise classifications — faster — and timely treatment recommendations along their patient journey.”

The DeLorean/SambaNova AI solution is subscription-based, can be hosted in the cloud or on-premises, and is extensible to other areas of the business. Labs across the country can deploy the solution for tracking states like diabetes, heart disease or cancer.

“The DeLorean/SambaNova AI solution provides for improved value-based care with AI and has the ability to significantly improve patient outcomes,” said Rodrigo Liang, CEO and co-founder of SambaNova Systems. “We’re pleased to work with DeLorean AI and Ascend to showcase how AI technology can truly revolutionize the renal care industry.”

ABOUT DELOREAN ARTIFICIAL INTELLIGENCE

DeLorean Artificial Intelligence strives to be the most HUMAIN AI in the world through building sentient and semi-sentient systems of intelligence to address healthcare, business and economic challenges for large fortune 500 companies and governments. DeLorean AI currently offers services in the Healthcare, Life Sciences, and Financial industries. We offer our services in the form of AI as as Service (AIaas). For more information, please visit us at deloreanai.com or contact us at fluxcapacitor@deloreanai.com. Follow DeLorean AI on LinkedIn.

Back to Press
Previous
|
Next